Telesis Bio appoints Eric Esser as CEO; shifts focus to Gibson SOLA EDS and BioXp mRNA

Telesis Bio Inc.

Eric Esser named President and CEO effective April 16, 2024, replacing founder Todd Nelson who remains on board.
Esser receives $490k base salary, 100% target bonus, 100k RSUs, and 200k stock options.
Operating expenses reduced from $14.3M (Q4 2022) to $10.8M (Q4 2023), extending cash runway.
Commercial focus on Gibson SOLA enzymatic DNA synthesis; secured co-development deal with automation provider.
BioXp focused on mRNA synthesis; distribution agreement with Avantor expands channel reach.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Esser

President and Chief Executive Officer

Telesis Bio Inc.

Effective: 2024-04-16
Filed: April 18, 2024, 7:59 PM ET

Eric Esser, who had been serving as the Company's President and Chief Operating Officer, assumed the position of President and CEO for the Company, effective as of April 16, 2024

Role change

Todd R. Nelson

Chief Executive Officer

Telesis Bio Inc.

Effective: 2024-04-16
Successor: Eric Esser
Filed: April 18, 2024, 7:59 PM ET

Todd R. Nelson, Ph.D., Founder, Chief Executive Officer (CEO) of the Company and member of the Company’s Board of Directors (the Board), will cease serving as the Company's CEO, effective as of April 16, 2024, and will remain a member of the Board

Appointed

Eric Esser

Class II Director

Telesis Bio Inc.

Effective: 2024-04-16
Filed: April 18, 2024, 7:59 PM ET

the Board approved the expansion of the Board from seven to eight members and appointed Mr. Esser to serve as a Class II director, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Esser was appointed as President and Chief Executive Officer at Telesis Bio Inc..

Action: assumed position
Role: President and Chief Executive Officer

Exact text from the filing

Eric Esser, who had been serving as the Company's President and Chief Operating Officer, assumed the position of President and CEO for the Company, effective as of April 16, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd R. Nelson changed role as Chief Executive Officer at Telesis Bio Inc..

Action: ceased serving as CEO
Role: Chief Executive Officer

Exact text from the filing

Todd R. Nelson, Ph.D., Founder, Chief Executive Officer (CEO) of the Company and member of the Company’s Board of Directors (the Board), will cease serving as the Company's CEO, effective as of April 16, 2024, and will remain a member of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Esser was appointed as Class II Director at Telesis Bio Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

the Board approved the expansion of the Board from seven to eight members and appointed Mr. Esser to serve as a Class II director, effective immediately

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-045313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.